



TD2014MRPL

Summary of Major Modifications

The Technical Document on Minimum Required Performance Levels for Detection and Identification of Non-Threshold Substances has undergone a brief revision by WADA's Laboratory Expert Group (LabEG).

The new version of the document, TD2014MRPL, includes two modifications:

- i) The MRPL for formestane has been reduced from 150 ng/mL to 50 ng/mL to reflect the requirement to perform GC-C-IRMS analyses before reporting an Adverse Analytical Finding for samples containing formestane between 50 ng/mL and 150 ng/mL, and
- ii) It has been specified that for reporting an Adverse Analytical Finding for the non-permitted systemic administration of the glucocorticosteroid Budesonide, the laboratories shall determine the presence of the metabolite 6 β -hydroxy-budesonide (at levels higher than 30 ng/mL).